CN112245420A - 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物 - Google Patents

用于治疗或预防癌症和神经疾病的包括15-hepe的组合物 Download PDF

Info

Publication number
CN112245420A
CN112245420A CN202011269111.4A CN202011269111A CN112245420A CN 112245420 A CN112245420 A CN 112245420A CN 202011269111 A CN202011269111 A CN 202011269111A CN 112245420 A CN112245420 A CN 112245420A
Authority
CN
China
Prior art keywords
hepe
subject
cancer
composition
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011269111.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·克莱麦克斯
D·考夫兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Efimoen GmbH
Original Assignee
Efimoen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efimoen GmbH filed Critical Efimoen GmbH
Publication of CN112245420A publication Critical patent/CN112245420A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202011269111.4A 2015-07-21 2016-07-21 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物 Pending CN112245420A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195138P 2015-07-21 2015-07-21
US62/195,138 2015-07-21
CN201680049674.8A CN108025181A (zh) 2015-07-21 2016-07-21 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680049674.8A Division CN108025181A (zh) 2015-07-21 2016-07-21 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物

Publications (1)

Publication Number Publication Date
CN112245420A true CN112245420A (zh) 2021-01-22

Family

ID=56852299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011269111.4A Pending CN112245420A (zh) 2015-07-21 2016-07-21 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
CN201680049674.8A Pending CN108025181A (zh) 2015-07-21 2016-07-21 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680049674.8A Pending CN108025181A (zh) 2015-07-21 2016-07-21 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物

Country Status (6)

Country Link
US (3) US20170020836A1 (https=)
EP (2) EP3325094B1 (https=)
JP (2) JP2018520197A (https=)
CN (2) CN112245420A (https=)
ES (1) ES2851525T3 (https=)
WO (1) WO2017013492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
KR20220163468A (ko) * 2020-04-03 2022-12-09 애피뮨 리미티드 혈액학적 장애 및/또는 관련 질환을 치료 또는 예방하기 위한 15-hepe를 포함하는 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
KR20050083960A (ko) 2002-11-22 2005-08-26 닛폰 스이산 가부시키가이샤 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
AU2011253846A1 (en) * 2004-11-19 2012-01-12 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUN JONG HAN等: "Combined treatment with peroxisome proliferator activated receptor gamma ligands and gamma radiation induces apoptosis by PPARγ independent up regulation of reactive oxygen species induced deoxyribonucleic acid damage signals in non small cell lung", 《INT J RADIAT ONCOL BIOL PHYS》 *
KAO VANG等: "15 lipoxygenase metabolites of gamma linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids", 《PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS》 *

Also Published As

Publication number Publication date
CN108025181A (zh) 2018-05-11
US20180147173A1 (en) 2018-05-31
ES2851525T3 (es) 2021-09-07
EP3325094A1 (en) 2018-05-30
WO2017013492A1 (en) 2017-01-26
HK1256167A1 (en) 2019-09-13
JP2018520197A (ja) 2018-07-26
EP3861995A1 (en) 2021-08-11
US10716773B2 (en) 2020-07-21
US20210085628A1 (en) 2021-03-25
JP2021107406A (ja) 2021-07-29
EP3325094B1 (en) 2021-01-06
US20170020836A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
Russo et al. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity
US10231939B2 (en) Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
US20210085628A1 (en) Compositions comprising 15-hepe and methods of treating or preventing cancer and neurologic disease
JP6313418B2 (ja) セレンを含む組成物、並びにミトコンドリア機能不全と関連する疾患または状態の処置および予防のためのその使用
Abdelaziz et al. Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis
Shen et al. Sirtuins in intervertebral disc degeneration: current understanding
WO2020062951A1 (zh) 化合物及其用途
CN107405324A (zh) 包含15‑hepe的组合物和其使用方法
JP7285001B2 (ja) サフラナール製剤による肝臓癌治療の方法
CN117402059A (zh) 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
TWI434680B (zh) 二萜類化合物於治療攝護腺癌之用途
KR100439425B1 (ko) 잔토리졸을 포함하는 조성물 및 그 용도
US20240009163A1 (en) Anti-Oncogenic Phytochemicals and Methods and Uses for Treating Cancer
JP2020132625A (ja) 肝臓癌に対するサフラナールとソラフェニブの併用療法
JP5620391B2 (ja) リポ酸及びヒドロキシクエン酸を有効成分として含む薬学的組み合わせ
TWI469784B (zh) 可治療癌症之藥學組合物
HK1256167B (en) Compositions comprising 15(s)-hepe for use in sensitizing cancer cells to radiation therapy
Liau et al. CDA Formulations as the Best Drugs to Turn Around Cancer Mortality from Escalation to Deceleration
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途
WO2020257952A1 (es) Efecto antiproliferativo de extracto de agarophyton chilensis en cáncer prostático
Weijie et al. Liguzinediol ameliorates doxorubicin-induced cardiotoxicity and potentiates the metabolic remodeling by activating the AMPK/SIRT3 pathway and represses Caspase-3/GSDME-mediated pyroptosis
TWI507196B (zh) 赤靈酸ｓ用於製造癌症治療藥物的新穎用途
Raja et al. Chronology of Anticancer Drugs and Their Development
JP2025161062A (ja) 単離ミトコンドリアを含む薬学的組成物及び胃癌の処置におけるその使用
KR100396526B1 (ko) 잔토리졸을 포함하는 항염증 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210122

WD01 Invention patent application deemed withdrawn after publication